Gene Panel Market Outlook:
Gene Panel Market size was valued at USD 3.76 billion in 2024 and is projected to reach USD 31.3 billion by the end of 2037, rising at a CAGR of 17.7% during the forecast period, 2025 to 2037. In 2025, the industry size of the gene panel is estimated at USD 4.43 billion.
In the U.S., the patient pool for the multigene panels includes people with having inherited risk of ovarian cancers. The National Cancer Institute reported that various genomic screening pilot programs in the U.S. conducted sequencing of 109 genes across 25,100 patients during 2016-2020. The diagnostic throughput gets support from the Medicare coverage policies. Various government and pharmaceutical companies are investing in conducting personalized treatment. The inclusion of the AI-enabled panel optimization is expected to lower the costs.
The supply chain for the gene panel supply includes reagents, software, etc, that need to remain compliant with the FDA regulations. The supply chain is volatile due to numerous interconnected factors, such as technological dependencies, regulatory hurdles, and shifting demand patterns. Also, there is a dependency on limited suppliers, and various single-source bottlenecks lead to shortages. Countries are overcoming this by including biotech funding to lower their foreign reliance. For instance, in China, “Made in China 2025” is promoting local sequencing technologies to remain less reliant on variable factors.
